ChemDiv, Inc. has announced the signing of a collaborative discovery research agreement with Siwa Biotech Corporation, Oklahoma City, OK.
Under the agreement, ChemDiv will be initiating a high-throughput screen for small molecule inhibitors of tyrosylprotein sulfotransferases. The collaboration provides Siwa Biotech with access to ChemDiv's expertise in chemistry systems and lead discovery. Financial terms of the collaboration were not disclosed.
"We are pleased that such a dynamic company as Siwa Biotech chose to work with ChemDiv team on this research program," said Dr. Ilya Okun, Vice President Biology and Chief Technology Officer at ChemDiv, Inc. "Over the years we have been continuously building upon our integrated services platform to provide our valued customers with strong and efficient support for all of their discovery and development needs."
"We are excited to initiate this collaborative discovery project with ChemDiv. The project has an excellent chance of success, based on ChemDiv's excellent track record in small molecule drug discovery," said Kevin L. Moore, M.D., President Siwa Biotech Corporation.